好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cognitive Trajectory in Concordant Clinical and Neuropathological Diagnosis of Alzheimer's Disease Compared to Clinical Mimics - A Retrospective Analysis of NACC Data (2005-2023)
Aging, Dementia, and Behavioral Neurology
P2 - Poster Session 2 (8:00 AM-9:00 AM)
3-002
To assess the longitudinal rate of cognitive trajectory in Alzheimer’s disease and clinical mimics.

Neuropathology at autopsy remains the standard for a final diagnosis of Alzheimer’s disease(AD) while other types of dementia(AD-mimics) confound the accuracy of a clinical diagnosis. Evidence suggests that those with a concordant diagnosis(AD-AD) perform significantly worse on neuropsychological inventories than AD-mimics at baseline and last visit.

De-identified information from the National Alzheimer’s Coordinating Center(NACC) was retrospectively reviewed to include participants with a clinical AD diagnosis at their last visit. Participants with moderate to frequent neuritic plaques and a Braak stage between III-VI were categorized as AD-AD under a modified version of the National Institute on Aging’s neuropathological change guidelines. Otherwise, they were AD-mimics, which may include but are not limited to Lewy bodies disease, frontotemporal dementia, vascular dementia, and hippocampal sclerosis. Statistical analyses were conducted on demographics and 14 neuropsychological batteries assessing attention, dementia severity, executive function, language, memory, processing speed, and visuospatial ability.

As of the December 2023 data freeze, 3013 participants met initial criteria and had neuropathology data available, of which 2351(78.03%) were AD-AD. AD-mimics were older at death(mean 82.14±9.82 vs. 88.51±8.32, p<0.001), less impaired on CDR at last visit(mean 12.64±5.36 vs. 8.73±6.15, p<0.001), and have a lower prevalence of APOE?4 alleles(60.12% vs. 30.37%, p<0.001). Further, AD-mimics had significantly higher neuropsychological scores at baseline except for visuospatial ability(p=0.65) and slower rates of decline(p<0.001) across all domains after adjusting for age at each visit, sex, and education level.

This review of clinical and autopsy data from NACC showed that AD-mimics represent 21.97% of clinical AD diagnoses and had better cognitive performance at baseline with a slower progression of decline compared to the AD-AD group. These findings contribute to the expanding knowledge base for distinguishing AD from other dementia subtypes, facilitating timely diagnosis and adequate care.

Authors/Disclosures
Cherry J. Barragan
PRESENTER
Mrs. Barragan has nothing to disclose.
Kassu Mehari Beyene, PhD Dr. Beyene has nothing to disclose.
Boris Decourt, PhD Dr. Decourt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Light House Pharmaceuticals. The institution of Dr. Decourt has received research support from National Institute on Aging. Dr. Decourt has received personal compensation in the range of $500-$4,999 for serving as a Reviewer with National Institute on Aging.
Marwan N. Sabbagh, MD, FAAN (Barrow Neurological Institute) Dr. Sabbagh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genetech=Roche. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Sabbagh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Synaptogenix. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant Health. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Anavex. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cognito Therapeutics. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Sabbagh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Sabbagh has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for CervoMed. Dr. Sabbagh has stock in Neurotau. Dr. Sabbagh has stock in Seq Biomarque. Dr. Sabbagh has stock in uMethod Health. Dr. Sabbagh has stock in Athira. Dr. Sabbagh has stock in Lighthouse Pharmaceuticals. Dr. Sabbagh has stock in Alzheon. The institution of Dr. Sabbagh has received research support from NIH. The institution of Dr. Sabbagh has received research support from ADDF.